Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the third quarter of 2009. The Company reported a net loss of $1.0 million, or $0.01 per share (basic and diluted), for the third quarter of 2009 compared with a net loss of $19.1 million, or $0.24 per share (basic and diluted), for the third quarter of 2008. The Company reported a net loss of $31.3 million, or $0.39 per share (basic and diluted), for the nine months ended September 30, 2009 compared with a net loss of $49.6 million, or $0.63 per share (basic and diluted), for the same period in 2008. During the third quarter of 2009, the Company recognized as revenue a $20.0 million milestone payment from Bayer HealthCare, as described below.

At September 30, 2009, cash, restricted cash, and marketable securities totaled $438.6 million compared with $527.5 million at December 31, 2008.

Current Business Highlights

ARCALYST® (rilonacept) - Inflammatory Diseases

The Company shipped $5.3 million of ARCALYST® (rilonacept) Injection for Subcutaneous Use to its U.S. distributors during the third quarter of 2009, compared to $4.3 million in the same quarter of 2008. Shipments during the first nine months of 2009 were $15.0 million compared to $6.7 million for the same period of 2008. ARCALYST, an interleukin-1 (IL-1) blocker, was approved in the United States in February 2008 for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The Company currently projects shipments of ARCALYST to its U.S. distributors to total approximately $20 million in 2009. In October 2009, rilonacept was approved under exceptional circumstances by the European Medicines Agency (EMEA) for the treatment of CAPS with severe
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical company, ... developing novel treatments for dry eye disease, today announced ... Allergan will acquire Oculeve in an all-cash transaction.  Under ... for a $125 million upfront payment and commercialization milestone ...
(Date:7/6/2015)... July 6, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. ... leading retail drugstore chain in China ... today announced that its board of directors has received ... from Simin Zhang , chairman of the board ... Holding Ltd., an investment vehicle wholly owned by Mr. ...
(Date:7/4/2015)... July 4, 2015 Adding ... patients with unresectable metastatic colorectal cancer in the ... organ Patients with unresectable metastatic colorectal ... liver experienced the greatest improvement in Progression-Free Survival ... SIR-Spheres Y-90 resin microspheres to a current first-line ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
(Date:7/5/2015)... , ... July 05, 2015 , ... Women’s Excellence ... college) at their Lake Orion location. The special consists of 2 months of unlimited ... Wellness, powered by Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... Plastic Surgeons published the results of an annual member survey , detailing ... United States. More recently, the group broke that raw data down into charts ...
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project Developer of ... expertise from the North American Board of Certified Energy Practitioners (NABCEP®), and is ... respected and well established national certification organization for renewable energy professionals. Designation as ...
(Date:7/3/2015)... ... , ... On June 30th SEO authority and veteran Internet ... "Page One Engine" . The program, which has been hailed as the ... well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, publishing an in-depth review ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Renowned rhinoplasty ... dates for the 2016 Dallas Rhinoplasty Symposium . To be held from March ... meeting will be held at the Westin Galleria Dallas. , Designed to take participants ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... earthquake to ravage China in decades, the task of ... onerous one. The 7.9-magnitude earthquake of 12 May devastated ... and causing extensive property damage. , Among the many ... enemy stray radioactive sources that could complicate relief ...
... 2008: Low bone mineral density in the hand is ... rheumatoid arthritis (RA) and indicates long-term prognosis, according to ... Annual Congress of the European League Against Rheumatism in ... density to be as effective predicting mortality as well-established ...
... France June 12, 2008 -- Biogen Idec ... the first dual-mechanism, lymphotoxin-; (LT-;) and LIGHT pathway ... diseases, including rheumatoid arthritis (RA), during the 2008 ... of Rheumatology at the Le Palais de Congrs ...
... Sales Already Exceed Q1 2008 and Q2 2007 Levels, - ... ... Surgeons, MONROVIA, Calif., June 12 STAAR ... invasive ophthalmic products, today announced that Visian ICL(TM),(Implantable Collamer Lens) sales in ...
... Laurent Claret Will Present Case Studies on the ... and Survival Benefits of Anticancer Agents, MOUNTAIN ... PHST ), a leading provider of software, strategic,consulting, ... announced that Laurent Claret, Ph.D., senior scientist,Pharsight Strategic ...
... A research abstract that will be presented on ... the Associated Professional Sleep Societies (APSS), finds a link ... adolescents with depressive episodes. , The study, authored by ... Brazil, focused on 303 individuals with pediatric bipolar disorder ...
Cached Medicine News:Health News:In quake's aftermath, Chinese sift through rubble for radioactivity 2Health News:Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 3Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 4Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 2Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 3Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 4Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 2Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 3Health News:Poor sleep linked to suicidal behavior among children and adolescents with depressive episodes 2Health News:Poor sleep linked to suicidal behavior among children and adolescents with depressive episodes 3
... OMNISCAN was launched in the U.S. in ... central nervous system (CNS) to detect lesions ... tissues. OMNISCAN has since received approval for ... pediatric CNS and body indications. OMNISCAN comes ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
... only isosmolar contrast medium (IOCM) available in the ... blood, VISIPAQUE was designed for patient safety and ... formulated with sodium and calcium in a ratio ... approval for use in children over one year ...
Medicine Products: